Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 47361-47370 Newer>

The Motley Fool February 24, 2011 Christopher Barker	They Broke the Mold With Yamana Gold As a deep value play for gold, Yamana remains in a class of its own.
BusinessWeek February 24, 2011 Patton & Tsang	Coffee Company Green Mountain: A Pricey Takeover? Green Mountain Coffee Roasters' shares have surged, but its single-cup brewing dominance may be threatened if Starbucks goes after the same business.
The Motley Fool February 24, 2011 Alex Pape	Rising Star Buy: Ampco-Pittsburgh (Again) Because it was so good the first time.
The Motley Fool February 24, 2011 Andrew Sullivan	4 Reasons Why DCF Valuations Fail Most discounted cash flow models are faulty.
The Motley Fool February 24, 2011 Anders Bylund	Brookdale Senior Living Shares Popped: What You Need to Know Shares of retirement home operator Brookdale Senior Living posted a mercurial 10.5% gain today amid heavy trading.
The Motley Fool February 24, 2011 Cindy Johnson	GrafTech International Shares Plunged: What You Need to Know GrafTech International Ltd. dropped 13% in intraday trading today after disappointing guidance outweighed strong fourth-quarter earnings.
The Motley Fool February 24, 2011 Tim Beyers	American Equity Life Shares Plunge and Recover: What You Need to Know Shares of American Equity Life suffered a staggering 15% loss early only to return to about even as of this writing.
The Motley Fool February 24, 2011 Brian D. Pacampara	Salix Pharmaceuticals Shares Plunged: What You Need to Know Shares of Salix Pharmaceuticals plummeted more than 20% after the company said it expects the Food and Drug Administration to deny its bid to gain expanded approval for its gastrointestinal antibiotic Xifaxan.
The Motley Fool February 24, 2011 Alex Pape	Why I Missed Out on a 24% Day for This Stock For the sake of education, let's take a look at the reflective process that had this analyst miss a 24% jump in American Public Education.
The Motley Fool February 24, 2011 Brian Orelli	Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%.
<Older 47361-47370 Newer> Return to current articles.